Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Gastrointestinal Cancer Industry?

In recent times, the market size for gastrointestinal cancer has seen swift expansion. Projected to escalate from a size of $24.09 billion in 2024 to $27.05 billion in 2025, it will present a compound annual growth rate (CAGR) of 12.3%. Factors contributing to growth during the historic period comprise of the increasing presence of gastrointestinal cancers, a rise in the consumption of tobacco and alcohol, population aging, unhealthy eating habits, and technological advancements in oncology diagnostics and therapy.

The market size for gastrointestinal cancer is forecasted to experience substantial growth in the upcoming years, reaching $42.45 billion in 2029 with a compound annual growth rate (CAGR) of 11.9%. The predicted growth within this period can be linked to the rising use of biomarker-driven therapies, increased recognition of early screening’s importance, the growth of the healthcare infrastructure, cancer care initiatives by the government, and a growing emphasis on minimally invasive methods. Significant trends during the forecast period involve advances in diagnostic tool technology, novel developments in targeted therapies, progress in immunotherapy, the escalated use of artificial intelligence in cancer treatments, and active research and development in precise oncology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24546&type=smp

What Forces Are Driving The Growth Of The Gastrointestinal Cancer Industry?

The burgeoning use of precision medicine, such as targeted therapies, is propelling the developmental trajectory of the gastrointestinal cancer market. These targeted therapies, which disrupt the growth of cancerous cells by acting on unique molecular targets while minimizing harm to healthy cells, offer more specificity than traditional treatments. By focusing on specific molecular pathways or genetic mutations, these therapies can effectively treat cancer in a more individualized way. Unlike former treatments like chemotherapy that indiscriminately damage both healthy and malignant cells, targeted therapies are specific to each patient’s condition. For gastrointestinal (GI) cancer, these treatments act on particular genes or proteins that regulate tumor growth, allowing for personalized and effective approaches. This method leads to improved patient outcomes and fewer side effects compared to traditional chemotherapy methods. For instance, the American Society of Gene & Cell Therapy (ASGCT), and Citeline, both US-based entities, reported in July 2023 that the number of gene therapies in Phase II increased by 5% from quarter one (Q1) 2023, 247 therapies, to quarter two (Q2), 260 therapies. As such, the growth of the gastrointestinal cancer market is being fueled by the increased adoption of targeted therapies.

What Is The Overview Of Market Segmentation In The Gastrointestinal Cancer Industry?

The gastrointestinal cancer market covered in this report is segmented –

1) By Cancer Type: Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Other Cancer Types

2) By Diagnostics: Endoscopy, Biopsy, Molecular Diagnostics, Imaging, Other Diagnostics

3) By Treatment: Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery, Other Treatments

4) By End-User: Hospitals, Oncology Centers, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Recurrent Colorectal Cancer, Metastatic Colorectal Cancer

2) By Stomach Cancer: Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST), Lymphoma, Carcinoid Tumors

3) By Esophageal Cancer: Adenocarcinoma, Squamous Cell Carcinoma, Small Cell Carcinoma, Other Rare Esophageal Tumors

4) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Endocrine (Neuroendocrine) Pancreatic Tumors, Metastatic Pancreatic Cancer, Resectable Or Unresectable Tumors

5) By Liver Cancer: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma, Hepatoblastoma, Secondary (Metastatic) Liver Cancer

6) By Other Cancer Types: Small Intestine Cancer, Anal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor

What Future Market Trends Are Projected For The Gastrointestinal Cancer Industry?

Key players in the gastrointestinal cancer market are concentrating their efforts on developing innovative solutions such as monoclonal antibody therapy to enhance patient survival rates while reducing the adverse effects associated with treatment. This form of treatment harnesses the power of lab-created antibodies that precisely recognize and attach to cancer cells, aiding the immune system in their targeted eradication. In a significant development, Astellas Pharma Inc., a pharmaceutical giant based in Japan, in September 2024, introduced VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-based chemotherapy. This treatment was approved by the European Commission. It represents a front-line defense for adults grappling with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinomas that show claudin 18.2 (CLDN18.2) expression in their tumors. With this approval, VYLOY becomes the pioneering and sole therapy in the European Union to target CLDN18.2, a biomarker present in approximately 38% of these patients. This approval draws its strength from the encouraging clinical trial results of the SPOTLIGHT and GLOW studies.

Who Are The Primary Players Operating Across The Global Gastrointestinal Cancer Market?

Major companies operating in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, Taiho Pharmaceutical Co. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-cancer-global-market-report

Which Region Offers The Most Growth Potential For The Gastrointestinal Cancer Market Through 2029?

North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24546&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model